How Australia Decides What Medicines Cost

Two separate approvals stand between a medicine and an Australian patient, and companies routinely underestimate the second. The Therapeutic Goods Administration decides whether a drug is safe and effective. The Pharmaceutical Benefits Advisory Committee decides whether it represents value for public money compared with what patients already receive. A medicine can be approved and still be commercially unavailable because no acceptable price was agreed.

How does cost-effectiveness assessment work?

By comparing the new medicine against the therapy patients currently receive, measuring both the additional health benefit and the additional cost. The result is expressed as a cost per unit of health gain, commonly a quality-adjusted life year, and the committee assesses whether that ratio represents acceptable value for public expenditure.

The comparison is what determines the outcome. A genuinely novel medicine for a condition with no existing treatment is assessed against supportive care and often lists readily. A medicine offering modest improvement over an existing cheap therapy faces a much harder test, because the additional benefit is small while the additional cost may be large.

This is why clinical trial design matters commercially as well as scientifically. A trial demonstrating superiority against placebo satisfies a regulator and may be inadequate for a reimbursement committee that wants superiority against current standard of care. Companies that design trials only for registration frequently discover the gap at the point of pricing negotiation.

Why does Australia pay less for medicines?

Because the government is effectively the only buyer, and it is willing to decline. A single national purchaser negotiating on behalf of the entire population has bargaining power no fragmented insurance market can match, and the credible threat of not listing a medicine at all is what converts that power into lower prices.

Additional mechanisms reinforce it. Price disclosure requires suppliers to report the discounted prices at which they actually sell to pharmacies, and the subsidised price is then reduced toward that level, which systematically drives down the cost of generic and off-patent medicines over time.

The patient outcome is favourable and the commercial consequence is real. Australians access most medicines at low out-of-pocket cost, and pharmaceutical companies earn less per patient in Australia than in the United States or several European markets. Companies sometimes delay Australian launches or decline to pursue listing for marginal products because the achievable price does not justify the effort.

What does this mean for Australian biotech?

That the domestic market is not the commercial objective. An Australian biotech developing a therapeutic is building for the United States and Europe, where prices and market size make development economics work, and treating Australia as a clinical and regulatory base rather than a revenue market.

Australia is genuinely competitive as that base. Clinical trial infrastructure is high quality, ethics approval is comparatively efficient, trial costs are lower than in the United States, and the research and development tax incentive provides a refundable offset that functions as substantial early-stage funding for pre-revenue companies.

The result is a well-established pattern: conduct early-phase trials in Australia using the tax incentive, generate data acceptable to international regulators, then partner with or sell to a company capable of funding late-stage development and global commercialisation. That pathway has produced genuine successes and it means the value frequently accrues offshore.

How is the system changing?

Under pressure from the arrival of very high-cost therapies. Gene therapies, cell therapies and advanced treatments for rare diseases can cost hundreds of thousands or millions of dollars per patient, delivered once, with benefits accruing over decades. A framework built for medicines taken daily at modest cost struggles to assess a single-administration treatment with lifetime effect.

Managed access and outcomes-based arrangements have emerged in response, under which the government pays over time or contingent on the treatment working, sharing risk between payer and manufacturer. These are administratively complex and represent a genuine departure from a simple listed price.

The broader tension is unresolved everywhere, not just in Australia. Health systems want innovation and cannot fund unlimited high-cost therapy, and every mechanism for reconciling the two is a rationing decision described in technical language. Australia’s system makes those decisions more explicitly than most, which is both its principal strength and the source of every controversy attached to it. Our profile of CSL covers a company operating on the manufacturer’s side of exactly this negotiation.

How do generics and biosimilars fit?

As the mechanism that recovers the cost of innovation. When a patent expires, generic manufacturers enter, prices fall sharply, and the savings fund the listing of new medicines. Australia’s price disclosure system accelerates this by requiring suppliers to report actual discounted selling prices, which then reduce the subsidised price.

Biosimilars are the harder version of the same idea. Because biological medicines are produced in living systems, a follow-on product cannot be chemically identical, only highly similar, which requires its own clinical evidence and raises questions about substitution at the pharmacy that do not arise with conventional generics.

The policy stakes are substantial because biologics are among the most expensive medicines on the schedule. Encouraging biosimilar uptake reduces expenditure significantly, and prescriber and patient confidence in substitution is the limiting factor. Australia has pursued this through prescribing incentives and education rather than mandatory substitution, which is slower and less contentious.

What is the community pharmacy role?

Dispensing is the delivery mechanism for the entire scheme, and community pharmacy is remunerated under a separate negotiated agreement covering dispensing fees, mark-ups and professional services. That agreement is renegotiated periodically and is one of the more contested processes in Australian health policy.

Pharmacy ownership and location rules add a further layer. Australian regulation restricts who may own a pharmacy and where new pharmacies may open relative to existing ones, which limits competition and supports the viability of community pharmacies in areas that might not otherwise sustain one.

The recurring policy argument is whether those protections serve patients or incumbents. Supporters argue they maintain a network of accessible pharmacies including in regional areas and preserve professional independence from retail pressure. Critics argue they suppress competition and keep costs higher than necessary. Neither position has prevailed, and the arrangement has proved durable across governments.

For completeness, the safety net matters as much as the co-payment for patients with chronic conditions. Once a household’s cumulative PBS spending in a calendar year exceeds a threshold, subsequent medicines are supplied at a reduced rate or free for the remainder of the year. That mechanism is what converts a per-prescription subsidy into genuine protection against the cost of managing multiple chronic conditions, and it is the feature that most distinguishes the Australian scheme from systems that cap only individual prescription costs.

What happens when a listing is refused?

The medicine remains available for private purchase at full price, which for most modern therapies means it is effectively unavailable to the great majority of patients. The company may resubmit with a lower price, additional evidence, or a narrower patient population where the cost-effectiveness case is stronger.

Resubmission is common and frequently successful. A first refusal typically identifies specific concerns – uncertainty in the clinical evidence, an inappropriate comparator, or simply a price too high for the benefit demonstrated – and companies address them and return. Several widely used medicines were listed only after multiple attempts.

The intervening period is where the human cost sits, and it is why these decisions generate such public pressure. Patients with the condition know the medicine exists, know it is available elsewhere, and are told it is not funded because the price offered exceeded what the health system judged reasonable. That is a defensible collective decision and an unbearable individual one, and no system has found a way to make it otherwise.

A final point on how the scheme is funded. PBS expenditure runs into the tens of billions of dollars annually and is one of the largest single items in the federal health budget, growing with an ageing population and with the arrival of higher-cost therapies. Every listing decision therefore has a fiscal dimension as well as a clinical one, and the cost-effectiveness threshold that governs those decisions is ultimately a statement about how much a health system is willing to pay for a year of quality life. Australia makes that judgement explicitly through a published process; most countries make it implicitly through what they decline to fund. The Australian approach is more transparent and considerably more contentious for exactly that reason.

The comparison most often drawn is with the United States, where no single national buyer negotiates and prices for the same medicines are frequently several times higher. Americans effectively fund a disproportionate share of global pharmaceutical research through those prices, and countries with monopsony purchasing benefit from innovation they contribute comparatively little to funding. That is an uncomfortable observation for every health system operating a cost-effectiveness threshold, and it is why proposals to link prices internationally periodically resurface without ever being adopted.

Frequently Asked Questions